tirzepatide weight loss trial on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 Impact of Body Mass Index,

Changes in vision can happen

ST: Writing original draft, Validation, Funding acquisition, Supervision, Writing review & editing

Tirzepatide can cause nausea and reduced food intake, which may lead to mild dehydration

Genetic Predispositions and Individual Discontinuation Risk Variants in GLP1R, FTO, MC4R, and GIPR genes influence appetite regulation, fat storage, and medication responsiveness

By opening a lower-cost entry point, Novo Nordisk is building a pipeline of future insured patients while preventing drop-offs during early dose escalation historically a vulnerable period when costs and side effects collide

and hypo-attenuated leaflet thickening providing consensus statements based on the latest data available and expert opinion